Department of Breast and Thyroid Surgery, Kawasaki Medical School, 577 Matsushima, Kurashiki, 701-0192, Japan.
Surg Today. 2012 Jul;42(7):633-8. doi: 10.1007/s00595-011-0091-7. Epub 2011 Dec 17.
To clarify the current trends in TSH suppression therapy for Japanese papillary carcinoma patents, a questionnaire survey was conducted among hospitals employing councilors of the Japanese Society of Thyroid Surgery.
The questionnaire consisted of 11 clinical questions divided into two sections.
One hundred and seventy-two questionnaires were mailed, and 89 hospitals (51.7%) responded and were included in the analyses. Total thyroidectomy (38.4%) was less common compared with non-total thyroidectomy. TSH suppression therapy was performed in 72 hospitals (80.7%). In 30 hospitals (41.7%), all patients were treated with TSH suppression therapy. The patients with advanced disease (33.3%), at high risk (28.6%) and with total thyroidectomy (19.0%) were selected at the remaining 42 hospitals. The majority of responding hospitals did not have a standard policy regarding the serum level of TSH for each patient (70.0%). The common criterion for the adjustment of serum TSH was the risk classification (73.9%). The duration of TSH suppression therapy was not specified in most hospitals (75.8%).
Our survey demonstrated that TSH suppression therapy is a common adjuvant therapy, but that the criteria for adjustment, the indications for and the duration of this therapy have not been standardized in Japan.
为了阐明日本甲状腺外科学会顾问所在医院中 TSH 抑制治疗的当前趋势，我们对这些顾问所在医院进行了问卷调查。
问卷由 11 个临床问题组成，分为两部分。
共寄出 172 份问卷，89 家医院（51.7%）回复并纳入分析。与非全甲状腺切除术相比，全甲状腺切除术（38.4%）的应用较少。72 家医院（80.7%）进行了 TSH 抑制治疗。30 家医院（41.7%）对所有患者进行 TSH 抑制治疗。在其余 42 家医院中，选择了晚期疾病（33.3%）、高危（28.6%）和全甲状腺切除术（19.0%）的患者。大多数回复医院没有针对每位患者 TSH 血清水平的标准政策（70.0%）。调整血清 TSH 的常见标准是风险分类（73.9%）。大多数医院未明确规定 TSH 抑制治疗的持续时间（75.8%）。
我们的调查表明，TSH 抑制治疗是一种常见的辅助治疗方法，但在日本，调整的标准、这种治疗的适应证和持续时间尚未标准化。
